Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Ulcerative Colitis

NI woman opens up on ulcerative colitis diagnosis and urges others not to ignore symptoms

Megan McNeill is urging others to use the online symptom checker if they're concerned

Belfast Live

Woman 'dreaded leaving the house' after condition left her needing toilet up to 16 times a day

Veterinary surgeon Emma Huntley was diagnosed with ulcerative colitis and experienced a range of crippling symptoms. She says having a stoma bag fitted - something she feared - has massively improved her life.

Daily Mirror

How the stoma bag I’d been dreading changed my life forever

Emma Huntley, 25, who lives in Carmarthen, Wales, was in agony from ulcerative colitis.

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Woman who got a stoma bag at 25 says it has given her back her life

Emma Huntley was in agony from ulcerative colitis before she got the bag

The Independent UK

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has accepted for review MediWound’s (NASDAQ:MDWD) recently re-submitted Biologics License Application (BLA) for its lead asset NexoBrid for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns. MediWound shares traded in a range of $1.6 to $1.76 on a day…

Benzinga

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

Benzinga

Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Mayo Clinic Q and A: How to manage symptoms of liver disease

DEAR MAYO CLINIC: My husband is 45 and has lived with irritable bowel syndrome for many years. He was recently diagnosed with primary sclerosing cholangitis. Are these two conditions related? We were told a liver transplant was likely in the future. Do all people require a transplant? Are other treatments…

Tribune News Service

Applied Molecular Shares Tumble After Disappointing Data From Mid-Stage Ulcerative Colitis Study

Applied Molecular Transport Inc (NASDAQ: AMTI) has

Benzinga

Firefighter suffering from 'invisible illness' has to go to the toilet 30 times a day

Catherine Hopkins started suffering swollen joints, belly pain and chronic fatigue at the age of 27 and was diagnosed with ulcerative colitis which has had a major impact on her quality of life

Daily Mirror

Seres Therapeutics Touts New Safety Data, Plans First FDA Approval For Microbiome Drug

Seres Therapeutics Inc (NASDAQ:MCRB) announced confirmatory results from ECOSPOR IV, an open-label study for SER-109 to prevent recurrent C. difficile infection (rCDI). The overall safety profile observed in ECOSPOR IV through 24 weeks indicated that SER-109 was well tolerated. The ECOSPOR III and ECOSPOR IV studies conclude the SER-109 Phase 3 development program. In ECOSPOR…

Benzinga

Lanarkshire student, 23, dies 13 days after cancer diagnosis as twin sister demands answers

Ryan Brown's family are planning to submit a formal complaint to NHS Lanarkshire as they believe he received "a neglectful lack of care".

Glasgow Live

Young Scot dies from bowel cancer 13 days after diagnosis as twin sister hits out at 'lack of care'

Ryan Brown's sister Hope believes there were multiple missed opportunities to diagnosis her sibling and is calling for more frequent testing for patients with ulcerative colitis.

Daily Record

Lilly Touts Encouraging Mirikizumab Data In Ulcerative Colitis Maintenance Setting

Eli Lilly And Co (NYSE:LLY) announced a data readout for the Lucent-2 Phase 3 study of mirikizumab after 52 weeks. The trial enrolled patients with ulcerative colitis who had initially responded to mirikizumab in a 12-week Lucent-1 study. The primary endpoint was clinical remission, with 49.9% of participants in the mirikizumab arm reaching…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Pfizer's Ulcerative Colitis Candidate Shows Remission In Over 30% Of Patients In Pivotal Studies

Pfizer Inc (NYSE:PFE) has announced detailed results from two pivotal studies from ELEVATE UC Phase 3 program evaluating etrasimod for active ulcerative colitis (UC). The drug, etrasimod, was Pfizer's key asset in its $6.7 billion deal for Arena Pharmaceuticals last year. UC is an inflammatory bowel disease that affects around 3.8 million people in North…

Investors Business Daily

Pfizer's Nearly $7 Billion Acquisition Of Arena Pharma Just Paid Off In A Big Way

Pfizer's nearly $7 billion takeover of Arena paid off Tuesday in ulcerative colitis treatment. The results could send Pfizer stock higher.

Benzinga

Surrozen Commences Phase 1 Study of SZN-1326 In Ulcerative Colitis

Surrozen, Inc. (NASDAQ: SRZN) announced that the first patient has been dosed in the Phase 1 clinical trial to evaluate its drug candidate SZN-1326 for the potential treatment of moderate to severe ulcerative colitis.

The Independent UK

New treatment available on NHS to ulcerative colitis sufferers in Scotland

The Scottish Medicines Consortium has approved the new tablet called filgotinib.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Connect Biopharma Stock Plunges As Ulcerative Colitis Candidate Flunks In Mid-Stage Study

Connect Biopharma Holdings Limited (NASDAQ:CNTB) announced topline results at 12 weeks from its Phase 2 trial for CBP-307 (CBP-307CN002) for ulcerative colitis. CBP-307 0.2 mg demonstrated a numerical reduction for the primary endpoint of least squares mean change from baseline in adapted Mayo Score at Week 12 that did not meet statistical significance. …

Benzinga

Why Protagonist Therapeutics Shares Are Crashing Today

Protagonist Therapeutics Inc (NASDAQ:PTGX) announced topline results from the Phase 2 IDEAL study of PN-943 in moderate-to-severe ulcerative colitis (UC) patients. 159 patients with moderate-to-severe active UC were randomized to either twice daily (BID) with 450 mg or 150 mg PN-943, or placebo, for 12 weeks. While the 450 mg BID dose did…

Benzinga

The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy

Here's a roundup of top developments in the biotech space over the last 24 hours:

Edinburgh Live

Teen who was 'too self-conscious' about symptoms diagnosed with chronic illness

Megan McNeil was suffering from extreme fatigue, weight loss and visiting the toilet 15-20 times an hour before being diagnosed with Ulcerative Colitis, with the now 21-year-old opening up about her journey

Daily Mirror

Woman diagnosed with chronic illness after years of embarrassment about symptoms

Megan McNeil, 21, was diagnosed with Ulcerative Colitis after she experienced symptoms such as passing blood when going to the bathroom

Benzinga

Protagonist Therapeutics Topline Data from Phase 2 IDEAL Study of PN-943 (450 mg BID) Miss Primary Endpoint

Protagonist Therapeutics (NASDAQ: PTGX) announced top-line results from the Phase 2 IDEAL clinical study evaluating PN-943 in patients with moderate-to-severe ulcerative colitis (UC).

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Irritable Bowel Syndrome

25 stories

Amyotrophic lateral sclerosis

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.